Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

St. Jude launches first U.S. trial of its renal denervation system. Universal decolonization reduces ICU infections better than screening-based approaches. More research news.

You may also be interested in...



St. Jude Halts U.S. Renal Denervation Trial, Citing Slow Patient Enrollment

Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.

New Products: St. Jude Renal Denervation; Zimmer Shoulder; Respicardia Sleep Apnea Pulse Generator

St. Jude’s next-generation EnligHTN renal denervation system earns a CE mark. Respicardia launches First implant pulse generator to treat central sleep apnea. FDA clears Zimmer shoulder system. GeneDX launches BRCA1 and BRCA2 genetic tests not long after Supreme Court overturns Myriad’s monopoly on the tests.

EuroPCR in Brief

New clinical data from St. Jude Medical’s and Boston Scientific’s trials of renal denervation devices to treat hypertension show progress in the development of these novel blood pressure therapies, but both companies remain behind Medtronic. More news from EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel